Oppenheimer analyst Jay Olson maintained an Outperform rating and $210 price target on Amgen after meeting with the company, saying he maintains his bullish stance. In a research note to investors, Olson says he is “encouraged” by Amgen’s comments on the current status of Enbrel, Repatha potential with the lower list price, Aimovig launch and CGRP market dynamics, the oncology pipeline and capital allocation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.